# Milk Thistle Liver Health Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/milk-thistle-liver-health-meta-analysis-evidence-review
Category: evidence-review
Summary: Milk Thistle Liver Health Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are
Last reviewed: 2026-05-21
Reviewed by: Migaku Evidence Review
# Milk Thistle Liver Health Meta-analysis: What the Evidence Says

## Quick Answer

Milk Thistle Liver Health Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 research article, 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Effectiveness of silymarin with lifestyle intervention in NAFLD and metabolic syndrome: a prospective single-arm study | research article | 4 | 2026-01-01 | 10.7573/dic.2025-12-5 |
| Silymarin as a phytopharmaceutical agent: advances in mechanistic insights, formulation strategies, and pre-clinical applications | preclinical study | 4 | 2025-11-27 | 10.3389/fphar.2025.1711653 |

## What The Sources Report

- The term ‘metabolic dysfunction-associated fatty liver disease' was coined in 2020 to stress this relationship, but it lacked global consensus. [Sukeepaisarnjaroen Wattana (2026); evidence level 4]
- To reduce stigma and improve diagnostic clarity, the expert panel endorsed the term ‘metabolic dysfunction-associated steatotic liver disease' (MASLD) in 2023;given the nearly identical prevalence rates for NAFLD (38.01%) and MASLD (37.9%), indicating substantial diagnostic overlap,the term MASLD is now preferred. [Sukeepaisarnjaroen Wattana (2026); evidence level 4]
- Recent mechanistic evidence suggests that these pathways converge on mitochondrial protection and the regulation of oxidative phosphorylation, contributing to their dual hepatocellular and neuroprotective actions. [Sayyad Mahewish (2025); evidence level 4]
- Increased production of key antioxidant and detoxification enzymes and cofactors. [Sayyad Mahewish (2025); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For milk thistle liver health meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Sukeepaisarnjaroen Wattana (2026). Effectiveness of silymarin with lifestyle intervention in NAFLD and metabolic syndrome: a prospective single-arm study. DOI: 10.7573/dic.2025-12-5. PMCID: PMC13082349. PMID: 41993723. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13082349/
- Sayyad Mahewish (2025). Silymarin as a phytopharmaceutical agent: advances in mechanistic insights, formulation strategies, and pre-clinical applications. DOI: 10.3389/fphar.2025.1711653. PMCID: PMC12695834. PMID: 41394134. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12695834/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.